Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melsmon is a pharmaceutical-grade human placental extract primarily used for the treatment of menopausal syndrome and climacteric symptoms. It is a complex biologic containing amino acids, peptides, vitamins, and minerals. The drug is thought to alleviate symptoms such as hot flashes, insomnia, and fatigue by modulating the hypothalamic-pituitary-adrenal (HPA) axis and exerting anti-inflammatory effects through the suppression of pro-inflammatory cytokines. Melsmon has been approved in several countries, including Japan and South Korea, for menopausal disorders and is administered via subcutaneous or intramuscular injection. Recent research also suggests potential therapeutic benefits in stress-induced neuroinflammation and depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human placental extract.